creatine has been researched along with Menopause in 8 studies
Menopause: The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.
Excerpt | Relevance | Reference |
---|---|---|
" It is likely that a higher dosage would be more effective, but would cause the potential endometrial effects." | 2.65 | Bone loss during oestriol therapy in postmenopausal women. ( Clark, AC; Garwood, J; Hart, DM; Kraszewski, A; Lindsay, R; Maclean, A, 1979) |
"We conducted a dose-response study in 23 postmenopausal women to compare the physiologic effects of transdermal estradiol and oral conjugated equine estrogens." | 1.27 | Biologic effects of transdermal estradiol. ( Alkjaersig, NK; Chetkowski, RJ; Eggena, P; Fletcher, AP; Hershman, JM; Judd, HL; Lu, JK; Meldrum, DR; Randle, D; Steingold, KA, 1986) |
"In patients with breast and prostate cancer hormone excretion patterns differ in a similar way from patterns in persons without cancer." | 1.24 | HORMONE EXCRETION PATTERNS IN BREAST AND PROSTATE CANCER ARE ABNORMAL. ( HOPKINS, CE; MARMORSTON, J; STERN, E; WEINER, JM, 1964) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (62.50) | 18.7374 |
1990's | 1 (12.50) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (12.50) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors | Studies |
---|---|
Smith-Ryan, AE | 1 |
Cabre, HE | 1 |
Eckerson, JM | 1 |
Candow, DG | 1 |
Liu, X | 1 |
Wang, L | 1 |
Peng, D | 1 |
Wang, Y | 1 |
Ren, M | 1 |
YAHIA, C | 1 |
TAYMOR, ML | 1 |
BUYTENDORP, A | 1 |
SORENSEN, AW | 1 |
STERN, E | 1 |
HOPKINS, CE | 1 |
WEINER, JM | 1 |
MARMORSTON, J | 1 |
Lindsay, R | 1 |
Hart, DM | 1 |
Maclean, A | 1 |
Garwood, J | 1 |
Clark, AC | 1 |
Kraszewski, A | 1 |
Packer, E | 1 |
Holloway, L | 1 |
Newhall, K | 1 |
Kanwar, G | 1 |
Butterfield, G | 1 |
Marcus, R | 1 |
Chetkowski, RJ | 1 |
Meldrum, DR | 1 |
Steingold, KA | 1 |
Randle, D | 1 |
Lu, JK | 1 |
Eggena, P | 1 |
Hershman, JM | 1 |
Alkjaersig, NK | 1 |
Fletcher, AP | 1 |
Judd, HL | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model[NCT04051320] | Phase 2 | 23 participants (Actual) | Interventional | 2020-01-02 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"This outcome measure determines the degree of irritability and reactive aggression in HS+ during hormone addback and its relationship to the target population. Irritability will be defined as score on the IDAS Ill Temper Scale. Reactive aggression will be defined as the number of point subtractions the participant makes during the Point Subtraction Aggression Paradigm.~The Point Subtraction Aggression Paradigm measures relational aggression (approach behavior) in response to frustration. In the task, participants are asked to press a button to ac" (NCT04051320)
Timeframe: Endpoint (week 6)
Intervention | correlation coefficient (Number) |
---|---|
Hormone Sensitive Women (HS+) | 0.18 |
Hormone Insensitive Women (HS-) | 0.03 |
"This outcome measure determines the degree of subcortical (amygdala, caudate, putamen, and nucleus accumbens) activation in HS+ during hormone addback and it's relationship to the target population. The activation in amygdala and ventral striatum (caudate, putamen, nucleus accumbens) regions of interest (ROIs) will be assessed during the Affective Posner Task.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: Endpoint (week 6)
Intervention | correlation coefficient (Number) |
---|---|
Hormone Sensitive Women (HS+) | 0.47 |
This outcome measure determines the extent to which irritability is characterized by dysfunctional reward processing during reproductive hormone challenge in HS+ and HS- by examining the correlation between the Inventory of Depressive and Anxiety Symptoms (IDAS) Ill Temper (i.e., irritability) Scale and threat attention bias. (NCT04051320)
Timeframe: Endpoint (week 6)
Intervention | correlation coefficient (Number) |
---|---|
Hormone Sensitive Women (HS+) | -0.35 |
Hormone Insensitive Women (HS-) | 0.11 |
This outcome measure determines the extent to which irritability is characterized by dysfunctional reward processing during reproductive hormone challenge in HS+ and HS- by examining the correlation between the IDAS Ill Temper (i.e., irritability) Scale and amygdala-medial PFC connectivity in HS+. (NCT04051320)
Timeframe: Endpoint (week 6)
Intervention | correlation coefficient (Mean) |
---|---|
Hormone Sensitive Women (HS+) | -0.13 |
Hormone Insensitive Women (HS-) | 0.49 |
This outcome measure determines the extent to which irritability is characterized by dysfunctional reward processing during reproductive hormone challenge in HS+ and HS- by examining the correlation between the IDAS Ill Temper (i.e., irritability) Scale and amygdala-medial PFC connectivity in HS+. (NCT04051320)
Timeframe: Endpoint (week 6)
Intervention | correlation coefficient (Number) |
---|---|
Hormone Sensitive Women (HS+) | -0.57 |
Hormone Insensitive Women (HS-) | -0.08 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left amygdala in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | -0.009866667 | -0.086876444 |
Hormone Sensitive Women (HS+) | 0.005316917 | -0.047401917 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left caudate in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.0077258 | -0.049988 |
Hormone Sensitive Women (HS+) | -0.043943333 | 0.059099917 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left nucleus accumbens in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.0691907 | -0.072512 |
Hormone Sensitive Women (HS+) | -0.028451818 | 0.031632727 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the left putamen in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.0383029 | -0.021029 |
Hormone Sensitive Women (HS+) | -0.001223462 | 0.048155385 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right amygdala in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.037334 | -0.15643 |
Hormone Sensitive Women (HS+) | -0.04544 | 0.022654 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right caudate in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.061407 | 0.0058011 |
Hormone Sensitive Women (HS+) | -0.069919077 | 0.045146154 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right nucleus accumbens in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.052685333 | -0.006394444 |
Hormone Sensitive Women (HS+) | 0.044384167 | -0.005181667 |
"This outcome measure determines the extent to which HS+ is characterized by BOLD activation of the right putamen in response to frustrative non-reward (FNR) in the Affective Posner Task during hormone addback relative to baseline in the target population.~The Affective Posner Task tests whether HS+ is characterized by reduced subcortical activation in response to frustration. This task is divided into 3 runs: during Run 1 (practice run), participants receive accurate feedback about their performance on the task and do not win or lose money; during Run 2, participants receive accurate feedback about their performance and win or lose 50 cents per trial; and during Run 3 (frustration), participants are told they must respond accurately to win money, but participants are given feedback that they responded too slowly on 60% of accurate trials, regardless of their performance." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Arbitrary Units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.002542222 | -0.080736333 |
Hormone Sensitive Women (HS+) | -0.007560692 | 0.036225385 |
"This outcome measure determines the extent to which irritability is characterized by dysfunctional threat processing during reproductive hormone challenge relative to baseline in HS+ and HS-. By examining amygdala-medial prefrontal cortex (PFC) connectivity in response to threatening faces on the implicit emotion face processing fMRI task in HS+ (compared with HS-) during hormone challenge relative to baseline.~The implicit emotion face processing task asks participants to identify the gender of angry, happy, and fearful faces at 50%, 100% and 150% emotion intensity presented in random order for 2000 milliseconds followed by jittered fixation. Trials appear in 3 blocks, generating 30 trials of each emotion at each intensity and 90 neutral face emotion trials." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | arbitrary units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.0213 | 0.00111 |
Hormone Sensitive Women (HS+) | 0.0247 | -0.0192 |
"This outcome measure determines the extent to which HS+ is characterized by reactive aggression during hormone addback relative to baseline in the target population. Reactive aggression will be defined as the number of point subtractions the participant makes during the Point Subtraction Aggression Paradigm.~Point Subtraction Aggression Paradigm measures relational aggression (approach behavior) in response to frustration. In the task, participants are asked to press a button to accrue money or press another button to subtract money from a (fictional) partner at no direct gain to themselves. Frustration is induced by periodic subtractions of their own money, which is attributed to the partner." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | Number of subtraction responses (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 129.20 | 54.90 |
Hormone Sensitive Women (HS+) | 103.08 | 34.62 |
"This outcome measure determines the extent to which irritability is characterized by dysfunctional threat processing during reproductive hormone challenge relative to baseline in HS+ and HS-. By examining amygdala-medial prefrontal cortex (PFC) Blood-oxygen-level-dependent (BOLD) connectivity in response to threatening faces on the implicit emotion face processing fMRI task in HS+ (compared with HS-) during hormone challenge relative to baseline.~The implicit emotion face processing task asks participants to identify the gender of angry, happy, and fearful faces at 50%, 100% and 150% emotion intensity presented in random order for 2000 milliseconds followed by jittered fixation. Trials appear in 3 blocks, generating 30 trials of each emotion at each intensity and 90 neutral face emotion trials." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | arbitrary units (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 0.0533 | 0.00804 |
Hormone Sensitive Women (HS+) | 0.0174 | -0.0114 |
"This outcome measure determines the extent to which irritability is characterized by dysfunctional threat processing during reproductive hormone challenge relative to baseline in HS+ and HS- by examining threat attention bias assessed during the visual dot-probe paradigm.~The Visual Dot-Probe Paradigm asks participants to detect a target stimulus that is embedded in a matrix of distracting stimuli (e.g., a target stimulus, an angry face, might be embedded in a matrix of neutral distractor faces). Attention biases are inferred from faster response times to detect a threatening stimulus in a matrix of neutral stimuli relative to response time to detect neutral stimuli in neutral matrices. Thus, positive times reflect attention bias toward threat, whereas negative times reflect attention bias away from threat." (NCT04051320)
Timeframe: up to 6 weeks
Intervention | attention bias in milliseconds (Mean) | |
---|---|---|
Baseline (Visit 3) | Hormone Addback (Visit 6) | |
Hormone Insensitive Women (HS-) | 36.92 | -42.35 |
Hormone Sensitive Women (HS+) | -0.57 | -9.04 |
1 review available for creatine and Menopause
Article | Year |
---|---|
Creatine Supplementation in Women's Health: A Lifespan Perspective.
Topics: Adult; Affect; Aged; Body Composition; Brain; Creatine; Dietary Supplements; Exercise; Female; Human | 2021 |
1 trial available for creatine and Menopause
Article | Year |
---|---|
Bone loss during oestriol therapy in postmenopausal women.
Topics: Adult; Alkaline Phosphatase; Bone and Bones; Calcium; Clinical Trials as Topic; Creatine; Double-Bli | 1979 |
6 other studies available for creatine and Menopause
Article | Year |
---|---|
[Effects of estrogen replacement therapy on cognitive function of ovariectomized rats].
Topics: Animals; Aspartic Acid; Cognition; Creatine; Disease Models, Animal; Estradiol; Estrogen Replacement | 2014 |
DAY-TO-DAY VARIATION IN LH EXCRETION IN CARCINOMA OF THE ENDOMETRIUM AND NORMAL MENOPAUSE.
Topics: Creatine; Creatinine; Endometrium; Female; Gonadotropins; Gonadotropins, Pituitary; Humans; Luteiniz | 1964 |
THE KIDNEY FUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS IN RELATION TO THE COMMENCEMENT OF THE DISEASE. VI.
Topics: Adolescent; Arthritis; Arthritis, Rheumatoid; Creatine; Creatinine; Female; Geriatrics; Humans; Kidn | 1964 |
HORMONE EXCRETION PATTERNS IN BREAST AND PROSTATE CANCER ARE ABNORMAL.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Aged; Androsterone; Breast Neoplasms; Creatine; Creatinine | 1964 |
Effects of estrogen on daylong circulating calcium, phosphorus, 1,25-dihydroxyvitamin D, and parathyroid hormone in postmenopausal women.
Topics: Aged; Calcitriol; Calcium; Circadian Rhythm; Creatine; Cyclic AMP; Estrogens; Female; Humans; Hydrox | 1990 |
Biologic effects of transdermal estradiol.
Topics: Administration, Oral; Administration, Topical; Blood Coagulation Factors; Calcium; Carrier Proteins; | 1986 |